CytoVale is a medical diagnostics firm commercializing groundbreaking microfluidic technology developed at UCLA by one of the firm's founders. With an assembled team of biologists, data scientists, and engineers, the firm is focused on enabling rapid, cost-effective diagnostics across critical care, oncology, and further indications with the firm's novel microfluidic platform allowing investigators to probe individual cells to quantify the mechanical signatures of disease. Using cell mechanics and machine learning, and structured around a new class of biomarkers and applying this first to sepsis -- condition where early detection can dramatically improves patient outcomes and reduces treatment cost -- the firm enrolled a multi-hundred patient clinical study of CytoVale's flagship product in early sepsis detection in the emergency department. If proven effective, the approach has the potential to significantly reduce morbidity and mortality, decrease healthcare costs, and satisfy large diagnostic market.
